Wall Street analysts expect Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) to report ($1.08) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Anthera Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($1.11) and the highest estimate coming in at ($1.06). Anthera Pharmaceuticals reported earnings of ($2.80) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 61.4%. The firm is scheduled to announce its next quarterly earnings results on Tuesday, August 8th.

On average, analysts expect that Anthera Pharmaceuticals will report full year earnings of ($4.96) per share for the current financial year, with EPS estimates ranging from ($5.33) to ($4.53). For the next financial year, analysts anticipate that the company will post earnings of ($3.95) per share, with EPS estimates ranging from ($5.65) to ($2.86). Zacks’ earnings per share averages are a mean average based on a survey of research firms that follow Anthera Pharmaceuticals.

Anthera Pharmaceuticals (NASDAQ:ANTH) last announced its quarterly earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($2.03) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.47) by $0.56.

ANTH has been the topic of a number of recent research reports. Zacks Investment Research downgraded Anthera Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 8th. ValuEngine downgraded Anthera Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. Finally, Jefferies Group LLC decreased their price objective on Anthera Pharmaceuticals from $8.00 to $6.40 and set a “hold” rating on the stock in a research report on Monday, March 6th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and two have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $10.21.

WARNING: This story was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another domain, it was stolen and reposted in violation of United States and international trademark and copyright laws. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/06/28/zacks-analysts-expect-anthera-pharmaceuticals-inc-anth-will-announce-earnings-of-1-08-per-share.html.

Shares of Anthera Pharmaceuticals (NASDAQ:ANTH) remained flat at $1.69 during trading on Wednesday. The company had a trading volume of 10,160 shares. The stock’s market capitalization is $17.03 million. The stock’s 50-day moving average price is $1.87 and its 200 day moving average price is $1.06. Anthera Pharmaceuticals has a 1-year low of $1.54 and a 1-year high of $32.00.

Several large investors have recently modified their holdings of ANTH. Sabby Management LLC increased its position in Anthera Pharmaceuticals by 1,809.7% in the first quarter. Sabby Management LLC now owns 1,757,697 shares of the biopharmaceutical company’s stock valued at $748,000 after buying an additional 1,665,655 shares during the last quarter. Goldman Sachs Group Inc. increased its position in Anthera Pharmaceuticals by 1,376.1% in the first quarter. Goldman Sachs Group Inc. now owns 359,982 shares of the biopharmaceutical company’s stock valued at $153,000 after buying an additional 335,595 shares during the last quarter. UBS Group AG increased its position in Anthera Pharmaceuticals by 9.9% in the first quarter. UBS Group AG now owns 375,989 shares of the biopharmaceutical company’s stock valued at $160,000 after buying an additional 33,901 shares during the last quarter. Geode Capital Management LLC increased its position in Anthera Pharmaceuticals by 16.2% in the first quarter. Geode Capital Management LLC now owns 355,172 shares of the biopharmaceutical company’s stock valued at $151,000 after buying an additional 49,391 shares during the last quarter. Finally, Vanguard Group Inc. increased its position in Anthera Pharmaceuticals by 49.1% in the first quarter. Vanguard Group Inc. now owns 2,691,639 shares of the biopharmaceutical company’s stock valued at $1,145,000 after buying an additional 886,910 shares during the last quarter.

Anthera Pharmaceuticals Company Profile

Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.

Get a free copy of the Zacks research report on Anthera Pharmaceuticals (ANTH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Anthera Pharmaceuticals (NASDAQ:ANTH)

Receive News & Ratings for Anthera Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.